1007 Pfizer Sangamo
Yuliya Baranych / iStock / Getty Images Plus

Product Development

First patient dosed in Phase III hemophilia A trial could narrow gap between Pfizer/Sangamo and BioMarin

One-year follow up for giroctocogene fitelparvovec will occur around the same time as BioMarin’s two-year follow-up on Roctavian


Read the full 441 word article

How to gain access

Continue reading with a
two-week free trial.